Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | GCGR | P47871 | 4/20 | 0.41 |
| ▸ | USP5 | P45974 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.40 |
| ▸ | APAF1 | O14727 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.38 |
| ▸ | PPARD | Q03181 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2653731 | 0.95 | HAO1 (0.46) | HAO1CYP2D6GCGRHDAC8HDAC6 | |
| SCHEMBL2647125 | 0.91 | CYP2D6 (0.45) | HAO1CYP2D6GCGRUSP5BCL2L1 | |
| SCHEMBL2654247 | 0.90 | LMNA (0.43) | HAO1CYP2D6GCGRHDAC8HDAC6 | |
| SCHEMBL2647568 | 0.90 | GCGR (0.45) | HAO1CYP2D6GCGRAPAF1 | |
| SCHEMBL2660182 | 0.90 | GCGR (0.45) | HAO1CYP2D6GCGRAPAF1 | |
| SCHEMBL6917469 | 0.89 | GCGR (0.43) | HAO1CYP2D6GCGRHDAC8HDAC6 | |
| SCHEMBL6755406 | 0.89 | GCGR (0.49) | HAO1CYP2D6GCGRAPAF1 | |
| SCHEMBL6756859 | 0.89 | GCGR (0.49) | HAO1CYP2D6GCGRAPAF1 | |
| SCHEMBL2646694 | 0.89 | GCGR (0.49) | HAO1CYP2D6GCGRAPAF1 | |
| SCHEMBL2653410 | 0.88 | CYP2D6 (0.44) | HAO1CYP2D6GCGRBCL2L1MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040152750-A1 | Novel glucagon antagonists | NOVO NORDISK A/S (DK) | 2004-08-05 | — | — | US | disclosed |
| WO-2004056763-A2 | NOVEL GLUCAGON ANTAGONISTS | NOVO NORDISK A/S (DK) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152750-A1 | Novel glucagon antagonists | GLP1R, GCGR, GIPR | HAO1 3706/4885CYP2D6 4521/4885GCGR 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.